Nabumetone: Nursing Drug Guide, GI Bleeding Risk & Hold Rules
Nabumetone is a once-daily NSAID prodrug converted in the liver to active 6MNA—do not assume it is safer because dosing is nightly. Before every dose, reconcile duplicate NSAIDs, screen for aspirin-sensitive asthma, and watch for GI bleeding and rising creatinine when nabumetone stacks with anticoagulants, ACE inhibitors, or diuretics.
NSAIDs including nabumetone increase the risk of serious cardiovascular thrombotic events (myocardial infarction and stroke) and serious GI adverse events (bleeding, ulceration, perforation), which can be fatal. Nabumetone is contraindicated for peri-operative pain in CABG surgery and in patients with aspirin-sensitive asthma or prior serious NSAID reactions. Although nabumetone is often prescribed once daily at bedtime, it carries the same boxed warning as other NSAIDs—nurses must still catch duplicate NSAID exposure (scheduled nabumetone plus home ibuprofen, naproxen, or ketorolac) and monitor for acute kidney injury in patients with heart failure, renal impairment, or prior peptic ulcer or GI bleeding. Use the lowest effective dose for the shortest duration and escalate immediately for melena, hematemesis, oliguria, chest pain, or stroke symptoms.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before nabumetone: reconcile all NSAIDs, verify no aspirin-sensitive asthma, and check renal function and bleeding risk when warfarin, diuretics, or ACE inhibitors are co-prescribed. Hold for melena, oliguria, chest pain, or duplicate NSAID orders—the once-daily prodrug schedule does not reduce boxed-warning GI or cardiovascular harm.
Most common brand names
Nabumetone is available as generic tablets and was marketed as Relafen. U.S. labeling supplies 500 mg, 750 mg, and 1000 mg film-coated tablets. Patients may say “Relafen” while the MAR lists generic nabumetone—always verify strength and once-daily timing at reconciliation.
Do not confuse nabumetone with naproxen (sound-alike NSAID with different dosing) or with memantine (Namenda)—similar syllables but unrelated drug classes. Confirm the generic name and tablet strength (500, 750, or 1000 mg) on every order read-back.
Why we give it — Indications
Nabumetone is a nonselective NSAID prodrug indicated only for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis per prescribing information. It is not labeled for general mild-to-moderate pain, fever, or dysmenorrhea. Nurses must match the order to labeled arthritis indications and ensure no duplicate NSAID exposure from home products.
| Use | Detail |
|---|---|
| Osteoarthritis | Relief of signs and symptoms of osteoarthritis per nabumetone tablet labeling. |
| Rheumatoid arthritis | Relief of signs and symptoms of rheumatoid arthritis; labeling notes use with gold, d-penicillamine, and corticosteroids in controlled trials. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Nabumetone is a naphthylalkanone NSAID prodrug. After oral absorption, it undergoes hepatic biotransformation to the active metabolite 6-methoxy-2-naphthylacetic acid (6MNA), a potent inhibitor of prostaglandin synthesis. Unchanged nabumetone is not detected in plasma. Like other NSAIDs, nabumetone carries a boxed warning for serious cardiovascular thrombotic events and serious GI bleeding. NSAIDs may reduce renal perfusion in patients who depend on prostaglandins—especially when combined with furosemide, thiazides, or ACE inhibitors such as lisinopril.
Dosing overview
Use the lowest effective dose for the shortest duration consistent with treatment goals. Verify indication (OA or RA only), hepatic and renal function, concurrent anticoagulant or diuretic therapy, and all other NSAID sources before administration. Dosages greater than 2000 mg per day have not been studied per labeling.
Administration tip: Food increases the rate of 6MNA absorption but does not change total exposure—may take with or without food per labeling.
Missed dose: Not specified in the reviewed prescribing information. If a once-daily dose is missed, give when remembered unless the next scheduled dose is near—do not double doses without prescriber direction.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption | ~80% of oral dose recovered in urine; nabumetone converted rapidly to 6MNA (~35% of 1000 mg dose) | Active drug is the metabolite, not parent nabumetone |
| Tmax (6MNA) | ~3–4 hours at steady state (range 1–12 h in studies) | Once-daily HS dosing aligns with overnight peak; reassess morning stiffness and function |
| Half-life (6MNA) | ~24 hours (22.5–29.8 h in labeling table) | Long active metabolite half-life—GI and renal risk persists even with single daily dose |
| Duration | Supports once-daily chronic regimens up to 2000 mg/day studied | Do not add another NSAID while nabumetone is on the MAR or home list |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Perform medication reconciliation—screen for duplicate NSAIDs, aspirin, anticoagulants, ACE inhibitors, ARBs, and diuretics
- Review allergy history: nabumetone, aspirin/NSAID reactions, aspirin-sensitive asthma, prior serious NSAID skin reactions
- Assess cardiovascular history, blood pressure, edema, renal function (BUN/creatinine), and prior GI bleeding or ulcer disease
- Confirm surgical plan—hold per protocol before CABG; NSAIDs are contraindicated for CABG pain
Contraindications
- Known hypersensitivity to nabumetone or product excipients
- History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs
- Use in the setting of coronary artery bypass graft (CABG) surgery
- Prior serious skin reactions to NSAIDs (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) per labeling warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Warfarin / anticoagulants | Synergistic GI bleeding risk; 6MNA may displace protein-bound drugs | Monitor INR and bleeding; report melena, hematuria, or bruising when combined with warfarin |
| Other NSAIDs / aspirin | Additive GI bleeding and cardiovascular risk; concomitant aspirin not generally recommended | Do not administer duplicate NSAID therapy without prescriber intent; clarify low-dose aspirin plans |
| ACE inhibitors / ARBs / diuretics | NSAIDs may diminish antihypertensive effect and reduce natriuretic effect of furosemide and thiazides | Monitor blood pressure, weight, edema, and renal trends when diuretics or ACE inhibitors are co-administered |
| Lithium / methotrexate | NSAIDs may increase lithium levels and enhance methotrexate toxicity per NSAID class labeling | Flag to pharmacy; monitor toxicity symptoms when combined with methotrexate per institutional protocol |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: 500 mg, 750 mg, and 1000 mg film-coated tablets. Swallow whole with water; may take with or without food. Food increases absorption rate of 6MNA but not total exposure per labeling.
Once-daily timing: Labeling recommends 1000 mg as a single daily dose; many prescribers give at bedtime for arthritis. Confirm whether the order is HS or another fixed time and document adherence.
- Confirm home OTC NSAIDs and low-dose aspirin are documented after reconciliation
- Document indication, dose, route, time, and joint pain or function before and after dose when ordered
- Ensure fall-risk precautions in older adults with orthostatic symptoms, especially when bleeding or anemia develops
Cardiovascular and GI risks increase with higher cumulative NSAID exposure and longer duration. Count all NSAID sources—scheduled nabumetone plus home ibuprofen, naproxen, or ketorolac—before administering. The long 6MNA half-life does not permit “safe” overlap with another NSAID later the same day.
Expected therapeutic response
- Reduced joint pain, morning stiffness, or swelling in OA or RA using structured pain assessment and mobility goals
- Improved function with daily activities when inflammation is controlled
- No new GI bleeding, blood pressure elevation, edema, or renal function decline while therapy continues
Red flags — Stop and act
Hold nabumetone and escalate immediately when serious NSAID complications are suspected.
- Black or tarry stools, hematemesis, coffee-ground emesis, or severe abdominal pain suggesting GI bleeding
- Chest pain, sudden weakness, facial droop, slurred speech, or other stroke or heart attack symptoms
- New or worsening shortness of breath, rapid weight gain, or peripheral edema in patients with heart failure
- Decreased urine output, rising creatinine, or hyperkalemia suggesting renal injury
- Urticaria, facial swelling, wheezing, or anaphylaxis after a dose
- Jaundice, dark urine, or persistent nausea with rising AST/ALT on liver function tests
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Diarrhea | ≥1% (14% in U.S. trials) | Assess hydration; differentiate from GI bleeding if stools change character |
| Dyspepsia | ≥1% (13%) | Offer food if tolerated; hold and notify if severe or accompanied by melena |
| Abdominal pain | ≥1% (12%) | Assess for bleeding vs irritation; escalate if pain is acute or hemoglobin falls |
| Constipation, flatulence, nausea, positive stool guaiac | ≥1% (3–9% for starred reactions) | Monitor stool color and hemoglobin; positive guaiac warrants prescriber follow-up |
| Dizziness, headache, somnolence | ≥1% (3–9% for starred reactions) | Fall precautions in older adults; hold if sedation impairs safety |
| Pruritus, rash | ≥1% (3–9%) | Stop and notify for spreading rash, fever, or mucosal involvement |
| Edema | ≥1% (3–9%) | Monitor weight, blood pressure, and heart failure symptoms |
| GI bleeding, melena, perforation | <1% but serious; boxed warning | Hold NSAID, obtain hemoglobin, notify prescriber, prepare for urgent GI evaluation |
| MI / stroke | <1% reported; boxed warning | Hold dose, obtain vital signs and ECG per protocol, activate emergency pathway for acute symptoms |
| Anemia | <1% hematologic; may reflect occult GI blood loss | Trend hemoglobin; assess for melena when anemia develops on chronic NSAID therapy |
| Renal failure / interstitial nephritis | <1%; serious in susceptible patients | Monitor intake/output and renal function; hold if oliguria or rising creatinine |
| Hepatic failure / jaundice | <1%; rare fulminant hepatitis reported | Monitor LFTs when ordered; discontinue if persistent abnormalities or clinical hepatitis |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Symptoms following acute NSAID overdosage are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion and may occur after overdose per labeling.
There have been overdoses of up to 25 grams of nabumetone reported with no long-term sequelae following standard emergency treatment (activated charcoal, gastric lavage, IV H2-blockers, etc.) per prescribing information.
Management
- No specific antidote—provide symptomatic and supportive care
- Emesis and/or activated charcoal (60–100 g adults; 1–2 g/kg children) and/or osmotic cathartic if seen within 4 hours of ingestion with symptoms or after large overdose (5–10× usual dose)
- Forced diuresis, urine alkalinization, hemodialysis, or hemoperfusion may not be useful due to high protein binding of 6MNA
- Monitor airway, breathing, renal function, and GI bleeding
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Nabumetone vs naproxen—both are oral NSAIDs but differ in dosing (once-daily prodrug vs divided naproxen); read back generic name on verbal orders
- Nabumetone vs memantine (Namenda)—sound-alike names with entirely different indications; verify medication class before administration
- Strength errors—confirm 500 mg, 750 mg, or 1000 mg tablet; 1000 mg is a common starting dose but not the only strength supplied
- Duplicate NSAID therapy—scheduled nabumetone plus home ibuprofen, naproxen, or ketorolac is a common inpatient error
- Prodrug timing—do not assume a missed HS dose can be “made up” later the same day with another NSAID PRN
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May take with or without food; food speeds 6MNA absorption without changing total exposure. |
| HS dosing | Many arthritis regimens use bedtime dosing—confirm whether the patient took the prior night’s dose before giving a duplicate. |
| Anticoagulant patients | Prioritize bleeding assessments and INR trends at each visit when warfarin is co-ordered. |
| Diuretic / ACE inhibitor patients | Track weight, blood pressure, intake/output, and creatinine—NSAID-induced renal injury can develop within days. |
| Perioperative | Contraindicated for peri-operative CABG pain; hold per surgical NSAID protocols for other procedures. |
| Ask pharmacy when | Unclear total daily NSAID load, interaction with lithium or methotrexate, or renal dose adjustment in moderate/severe impairment. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher risk of GI bleeding, renal dysfunction, and cardiovascular events—use lowest dose, monitor closely, and avoid long duration without clear benefit. |
| Prior peptic ulcer / GI bleeding | Greater than 10-fold increased GI bleed risk with NSAIDs in patients with prior ulcer or bleeding per labeling—coordinate gastroprotection before restarting. |
| Heart failure / cardiovascular disease | Avoid in severe heart failure unless benefit outweighs risk; monitor blood pressure, edema, and symptoms of decompensation. |
| Renal impairment / dehydration | Treatment not recommended in advanced renal disease; use renal dose limits in moderate/severe impairment and monitor creatinine closely with ACE inhibitors or diuretics. |
| Pregnancy | Avoid at about 30 weeks gestation and later (ductus arteriosus closure). Between about 20 and 30 weeks, use lowest effective dose for shortest duration; consider ultrasound monitoring if use extends beyond 48 hours per labeling. |
| Lactation | Human milk excretion not known; 6MNA is excreted in rat milk—balance breastfeeding benefits against potential infant risk with the prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Joint pain and function using structured pain assessment and mobility goals
- GI status—stool color, hemoglobin trend, and symptoms of bleeding or ulcer
- Blood pressure, weight, edema, and heart failure symptoms
- Renal function and electrolytes when diuretics, ACE inhibitors, or ARBs are co-administered
- INR and bleeding signs when anticoagulants are used
- LFTs when hepatic risk factors or symptoms are present
Document
- Dose, route, time, indication, and functional response
- Allergy verification (NSAID, aspirin-sensitive asthma, prior serious skin reaction)
- Patient education on bleeding, cardiovascular symptoms, and when to seek urgent care
- Hold parameters communicated to patient and on the MAR per institutional policy
Patient teaching
- Take exactly as prescribed once daily (or as directed)—do not combine with other ibuprofen, naproxen, ketorolac, or aspirin products unless your prescriber directs you to
- Report black or bloody stools, vomiting blood, severe stomach pain, chest pain, shortness of breath, sudden weakness, facial swelling, or rash immediately
- NSAIDs can raise blood pressure and cause swelling—report rapid weight gain or ankle swelling
- Tell all clinicians you take nabumetone before surgery, dental procedures, or new prescriptions
- Pregnancy planning: discuss risks with your prescriber—avoid late-pregnancy use per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known nabumetone or NSAID hypersensitivity; aspirin-sensitive asthma history
- Suspected GI bleeding, melena, hematemesis, or severe abdominal pain
- Chest pain, stroke symptoms, or peri-CABG period when NSAIDs are contraindicated
- Acute kidney injury, oliguria, or rapidly rising creatinine while on NSAID plus diuretic/ACE inhibitor
- Supratherapeutic INR or active bleeding on anticoagulation without prescriber clearance
- Duplicate NSAID order would result from administering the scheduled dose (including hidden home ibuprofen/naproxen)
- Late pregnancy (avoid NSAIDs that may cause ductus arteriosus closure) unless prescriber documents exceptional benefit
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Nabumetone’s once-daily prodrug schedule can lull nurses into treating it like a low-risk bedtime tablet—but NSAID boxed warnings still apply. Build duplicate-NSAID checks, GI bleeding screens, and renal trend review into every administration pass, especially for older adults on anticoagulants, ACE inhibitors, and diuretics.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and no duplicate NSAID on the MAR, OTC list, or topical products
- Allergy screen includes NSAID reactions and aspirin-sensitive asthma
- Bleeding assessment and stool color when anticoagulated or prior PUD
- Blood pressure and weight trend when heart failure or diuretics are present
2. High-alert and safety badge
NSAID boxed warning — cardiovascular and GI riskTreat nabumetone with NSAID safety discipline: lowest dose, shortest duration, no duplicate NSAIDs, and immediate hold for bleeding or chest pain.
3. Clinical workflow: hold and question rules
- If the patient reports black stools while on nabumetone and warfarin, hold the dose and notify the prescriber before the next HS administration
- If admission reconciliation finds home ibuprofen plus a new nabumetone order, clarify with pharmacy before the first dose
- Reconcile chronic home NSAIDs at discharge—ensure patients know nabumetone replaces other NSAIDs unless prescriber directs otherwise
4. Critical teach-back questions
- “Which over-the-counter pain medicines should you avoid while taking nabumetone?” (Patient should name ibuprofen/naproxen/other NSAIDs and know acetaminophen is a different drug unless prescriber directs otherwise.)
- “What bleeding or heart symptoms mean you should seek care immediately?” (Black stool, vomiting blood, chest pain, sudden weakness, trouble breathing.)
5. Care coordination
Pharmacist: Review anticoagulant interactions, renal dose adjustment, duplicate NSAID therapy, and gastroprotection needs
Prescriber: Notify for GI bleeding, chest pain, rising creatinine, hypertensive crisis, or need for alternative analgesia in high-risk patients
🧠 Quick mental checklist
- Is the patient taking any other NSAID, aspirin, or OTC ibuprofen besides this nabumetone order?
- Any aspirin-sensitive asthma, NSAID allergy, or prior serious NSAID skin reaction?
- Any black stool, anemia, or abdominal pain while on nabumetone?
- On warfarin or anticoagulant—when was INR last checked?
- Creatinine, blood pressure, and intake/output trend acceptable before I give this dose?
Nabumetone NCLEX practice questions
Practice NCLEX-style clinical judgment practice for nabumetone using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, best next step, and documentation cloze—recognise duplicate NSAID risk → analyse renal/GI trends → prioritise holds → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Nabumetone 1000 mg PO HS — due 2100; last given yesterday 2100
- Lisinopril 20 mg PO daily — given 0800
- Furosemide 40 mg PO daily — given 0800
- Warfarin 5 mg PO daily — given 1800 yesterday; INR due today
- Acetaminophen 650 mg PO q6h PRN — not given in last 24 h
- Home ibuprofen 400 mg TID reconciled today—not on admission MAR
- Admission: Hgb 13.2 g/dL, Hct 39%, platelets 225 ×109/L, INR 2.0, BUN 24 mg/dL, creatinine 1.1 mg/dL
- Today 1400: INR 2.9 (goal 2–3); Hgb 11.4 g/dL (was 12.3 g/dL yesterday); BUN 32 mg/dL; creatinine 1.6 mg/dL; K+ 5.1 mEq/L
- Stool guaiac pending after melena report
- 0800 BP 132/78, HR 82, RR 16, SpO2 97% on room air
- 1400 BP 102/64, HR 96, RR 18; dizziness on standing
- Intake ~1200 mL oral fluids; urine output 450 mL (normally ~1500 mL/day); last void 6 hours ago
- Weight up 1.8 kg in 48 h; bilateral ankle edema 2+
- 72-year-old with osteoarthritis; history of peptic ulcer disease 4 years ago; took home ibuprofen until admission
- 1300: Patient reports “black, tarry” stools ×2 today; denies severe abdominal pain; increasing fatigue
- 1330: Nurse held 2100 nabumetone and warfarin pending prescriber call
- 1400: Reviewing case tabs before escalation
Answer key & rationale
Frequently asked questions
What GI and renal risks must nurses monitor with nabumetone?
Nabumetone carries the same NSAID boxed warning as other NSAIDs for serious cardiovascular thrombotic events and serious GI bleeding, ulceration, and perforation, which can be fatal. NSAIDs may precipitate renal injury in dehydration, heart failure, or with ACE inhibitors and diuretics. Once-daily dosing does not eliminate GI or renal risk—duplicate NSAID exposure remains a common preventable error.
When should a nurse hold nabumetone and contact the prescriber or pharmacist?
Hold for suspected GI bleeding, chest pain or stroke symptoms, acute kidney injury or oliguria, NSAID hypersensitivity, aspirin-sensitive asthma, CABG peri-operative period, or bleeding or INR concerns with warfarin. Also hold if duplicate NSAID therapy would occur from scheduled nabumetone plus home ibuprofen, naproxen, or other NSAIDs.
Can nabumetone be used with warfarin?
Nabumetone labeling states warfarin and NSAID effects on GI bleeding are synergistic, with higher combined bleeding risk than either drug alone. Exercise caution with concomitant use, monitor INR and bleeding signs, and report melena or supratherapeutic INR promptly.
What is the usual adult dose of nabumetone?
The recommended starting dose is 1000 mg once daily with or without food. Some patients may need 1500 to 2000 mg per day as a single or twice-daily dose. Dosages greater than 2000 mg per day have not been studied per labeling.
Is nabumetone safe during pregnancy or breastfeeding?
Avoid nabumetone at about 30 weeks gestation and later because of fetal ductus arteriosus closure risk. Between about 20 and 30 weeks, use the lowest effective dose for the shortest duration if NSAID therapy is necessary. Human milk excretion is not known; 6MNA is excreted in rat milk—balance breastfeeding benefits against potential infant risk with the prescriber.
What is the treatment for nabumetone overdose?
There is no specific antidote. Manage with symptomatic and supportive care per NSAID overdosage guidance. Activated charcoal may be considered for recent ingestions. Overdoses up to 25 grams have been reported without long-term sequelae after standard emergency care. Contact local poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Nabumetone tablets, USP — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef7c3da8-797f-4ea9-8999-53509785a0f7
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that NSAIDs increase heart attack and stroke risk.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-prescription-nsaids-increase-heart-attack-stroke-risk
-
Drugs and Lactation Database (LactMed). Nabumetone (LM192). Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM192/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.